| Name | Title | Contact Details |
|---|
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
We are a proudly Canadian healthcare company, providing diversified healthcare services across the country.
US Script, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Fresno, CA. To find more information about US Script, Inc., please visit www.usscript.com
SKT is a Ashland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A&M Biomedical is a Laguna Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.